Merck reported EUR1.96B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Adidas EUR 1.65B 492M Sep/2026
Adyen EUR 12.25B 1.82B Jun/2026
Akzo Nobel EUR 3.19B 430M Jun/2026
Alcon AG USD 1.7B 350M Sep/2026
Amadeus IT EUR 913.1M 235.9M Sep/2026
Amarin USD 156.51M 12.95M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 4.05B 3.74B Sep/2026
Bayer EUR 4.29B 1.44B Jun/2026
Beiersdorf EUR 1.28B 82M Jun/2026
Covestro EUR 474M 174M Jun/2026
Danone EUR 1.98B 364M Dec/2025
Fresenius EUR 1.28B 780M Jun/2026
Fresenius Medical Care EUR 1.1B 37.86M Sep/2026
Genmab DKK 1.5B 18M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 486M 27M Sep/2026
Henkel EUR 3.99B 1.28B Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Infineon EUR 1.38B 310M Sep/2026
Lakefront Biotherapeutics EUR 94.66M 41.3M Sep/2026
Linde USD 3.95B 12M Sep/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 1.96B 788M Jun/2026
Novartis USD 8.87B 1.25B Sep/2026
Philips EUR 2.75B 962M Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024